Palisade Bio Inc (PALI) Stock Price, Quote & News

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pha...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4900

Website: www.palisadebio.com

Address:

4600 South Syracuse Street, Suite 900, Denver, United States

STACKD0E Jul. 2 at 3:46 PM

$TENX $CSTE $PALI $RGNX $VOR

0 · Reply

Alidrisi Jun. 30 at 1:35 PM

$PALI .

0 · Reply

ronburgandy75 Jun. 30 at 11:56 AM

$PALI

0 · Reply

SkywalkerAR Jun. 30 at 8:42 AM

$PALI

0 · Reply

Bull_Not_Bullish Jun. 30 at 8:38 AM

$PALI 3+ today

0 · Reply

SkywalkerAR Jun. 30 at 8:30 AM

$PALI Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis Jun 29, 2026 https://palisadebio.com/palisade-bio-receives-fda-clearance-of-ind-for-pali-2108-and-plans-to-initiate-global-phase-2-ascentra-uc-study-in-ulcerative-colitis/

0 · Reply

SadyK189 Jun. 30 at 1:56 AM

Top Stocks to watch tomorrow 2 /2: $SLS $FCEL $ATLN $PALI $DGNX SLS is trending nicely on daily chart. Key support zone at 11.20 - 11.60. Next key level to test 17.30 - 17.70. Currently at 15.70 FCEL: Initially alerted at 11.80. Still trending strong on weekly and daily chart. Key support zone at 21 - 22.70. Next key level to test 34.45 - 34.85. Currently at 30.49 PALI: Getting up on 4hours chart. Key support zone at 1.65 - 1.80. Next key level to test 2.65 - 2.85. Currently at 2.24. It may take sometime though DGNX: Looking good on 4hours chart. 1 - 1.10 is acting as key support zone. Next key level to test 1.72 - 1.85. Currently at 1.37 ATLN: Looking good on daily chart. key support zone at 0.89 - 0.96. Next key level to test 1.45 - 1.65. Currently at 1.14

0 · Reply

Machiaveltrade Jun. 29 at 8:51 PM

$PALI and $ABVX my two precious….never sell 😁

0 · Reply

Machiaveltrade Jun. 29 at 8:26 PM

$PALI major position here and no sell …LT hold

0 · Reply

balzofsteel Jun. 29 at 6:19 PM

$PALI I’m balls deep in PALI. And I’m not ready to dump. More like I’m ready to hump . See y’all at $20

1 · Reply

Palisade Bio receives FDA clearance to start ulcerative colitis study

Jun 29, 2026, 8:30 AM EDT - 5 days ago

Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

Jun 11, 2026, 8:45 AM EDT - 23 days ago

Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors

Jun 9, 2026, 8:45 AM EDT - 25 days ago

Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium

Jun 4, 2026, 3:45 PM EDT - 4 weeks ago

Palisade Bio Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 7:00 AM EDT - 4 weeks ago

Palisade Bio Slides: Corporate presentation

May 27, 2026, 9:00 AM EDT - 5 weeks ago

Palisade Bio to Participate in the Jefferies Global Healthcare Conference

May 13, 2026, 7:00 AM EDT - 7 weeks ago

Palisade Bio Slides: Corporate presentation

2026-05-12T22:21:57.000Z - 7 weeks ago

Palisade Bio files $300M mixed securities shelf

May 12, 2026, 4:15 PM EDT - 7 weeks ago

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Palisade Bio Registration statement: Registration filing

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Palisade Bio Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 7 weeks ago

Palisade Bio Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 2 months ago

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Proxy statement: Proxy filing

Apr 16, 2026, 2:15 PM EDT - 2 months ago

Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 8:50 AM EDT - 2 months ago

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

2026-04-08T20:43:15.000Z - 3 months ago

Palisade Bio initiated with an Outperform at Wolfe Research

Apr 8, 2026, 9:00 AM EDT - 3 months ago

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Apr 1, 2026, 7:00 AM EDT - 3 months ago

Palisade Bio Slides: Corporate presentation

2026-03-31T20:38:39.000Z - 3 months ago

Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Palisade Bio Transcript: Study result

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Palisade Bio Press release: Study result

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Palisade Bio Slides: Study result

2026-03-30T20:19:16.000Z - 3 months ago

Palisade Bio announces topline data from PALI-2108 trial

Mar 30, 2026, 4:01 PM EDT - 3 months ago

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

2026-03-26T10:11:33.000Z - 3 months ago

Palisade Bio initiated with a Buy at H.C. Wainwright

Mar 20, 2026, 7:00 AM EDT - 3 months ago

Palisade Bio Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 3 months ago

Palisade Bio Slides: Corporate presentation

Mar 2, 2026, 3:10 PM EST - 4 months ago

Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:00 AM EST - 4 months ago

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Feb 26, 2026, 12:40 PM EST - 4 months ago

Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-24T21:52:07.000Z - 4 months ago

Palisade Bio initiated with a Buy at Stifel

2026-02-23T13:47:18.000Z - 4 months ago

Palisade Bio announces presentation of new data for PALI-2108

Feb 23, 2026, 8:40 AM EST - 4 months ago

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

2026-02-17T14:05:21.000Z - 4 months ago

Palisade Bio appoints Verstockt to its Clinical Advisory Board

Feb 17, 2026, 8:45 AM EST - 4 months ago

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Feb 9, 2026, 9:00 AM EST - 5 months ago

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 5, 2026, 8:45 AM EST - 5 months ago

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-29T13:50:44.000Z - 5 months ago

Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board

Jan 29, 2026, 8:45 AM EST - 5 months ago

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Jan 16, 2026, 8:30 AM EST - 6 months ago

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

2026-01-09T10:35:21.000Z - 6 months ago

Palisade Bio initiated with a Buy at B. Riley

2026-01-07T13:25:34.000Z - 6 months ago

Palisade Bio announces equity investment from Crohn’s & Colitis Foundation

Jan 7, 2026, 8:15 AM EST - 6 months ago

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

2025-12-30T13:45:55.000Z - 6 months ago

Palisade Bio granted Japanese patent covering PALI-2108

Dec 30, 2025, 8:35 AM EST - 6 months ago

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

2025-12-29T21:10:18.000Z - 6 months ago

Palisade Bio initiated with a Buy at Clear Street

2025-12-29T09:30:14.000Z - 6 months ago

Palisade Bio initiated with an Overweight at Piper Sandler

Dec 4, 2025, 10:30 AM EST - 7 months ago

Palisade Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-02T13:55:38.000Z - 7 months ago

Palisade Bio appoints James Izanec as VP, clinical development

BMY

Dec 2, 2025, 8:45 AM EST - 7 months ago

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Nov 25, 2025, 8:45 AM EST - 7 months ago

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

2025-11-11T17:45:32.000Z - 8 months ago

Palisade Bio price target raised to $8 from $2 at Maxim

Nov 10, 2025, 4:00 PM EST - 8 months ago

Palisade Bio Quarterly report: Q3 2025

Nov 3, 2025, 7:00 AM EST - 8 months ago

Palisade Bio Proxy statement: Proxy Filing

2025-10-28T12:50:12.000Z - 8 months ago

Palisade Bio appoints Sharon Skare as global head, clinical operations

Oct 28, 2025, 8:45 AM EDT - 8 months ago

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Oct 28, 2025, 8:00 AM EDT - 8 months ago

Palisade Bio Proxy statement: Proxy Filing

Oct 20, 2025, 8:45 AM EDT - 9 months ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 17, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Proxy statement: Proxy Filing

Oct 15, 2025, 6:00 PM EDT - 9 months ago

Palisade Bio Slides: Corporate Presentation

Oct 13, 2025, 8:45 AM EDT - 9 months ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 9, 2025, 5:00 PM EDT - 9 months ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 7, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Proxy statement: Proxy Filing

Oct 2, 2025, 4:05 PM EDT - 9 months ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 1, 2025, 9:20 AM EDT - 9 months ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Registration statement: Registration Filing

Sep 26, 2025, 4:05 PM EDT - 10 months ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 17, 2025, 9:00 AM EDT - 10 months ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Sep 5, 2025, 8:45 AM EDT - 10 months ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Sep 5, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Aug 25, 2025, 9:00 AM EDT - 11 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Palisade Bio Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 11 months ago

Palisade Bio Registration statement: Registration Filing

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Palisade Bio Quarterly report: Q2 2025

Aug 7, 2025, 9:15 AM EDT - 11 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Palisade Bio Proxy statement: Proxy Filing

Jul 31, 2025, 8:45 AM EDT - 1 year ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 23, 2025, 8:00 PM EDT - 1 year ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 22, 2025, 8:45 AM EDT - 1 year ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 9, 2025, 8:45 AM EDT - 1 year ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

May 27, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025, 8:00 AM EDT - 1 year ago

Palisade Bio Registration statement: Registration Filing

May 11, 2025, 6:00 PM EDT - 1 year ago

Palisade Bio Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 1, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Apr 9, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Palisade Bio Annual report: Q4 2024

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 4, 2025, 8:30 AM EST - 1 year ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Feb 20, 2025, 8:45 AM EST - 1 year ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio Transcript: Virtual Investor "Top 5 for '25"

Feb 10, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Jan 29, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 3, 2025, 5:20 PM EST - 1 year ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2024, 8:30 AM EST - 1 year ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 13, 2024, 4:05 PM EST - 1 year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

STACKD0E Jul. 2 at 3:46 PM

$TENX $CSTE $PALI $RGNX $VOR

0 · Reply

Alidrisi Jun. 30 at 1:35 PM

$PALI .

0 · Reply

ronburgandy75 Jun. 30 at 11:56 AM

$PALI

0 · Reply

SkywalkerAR Jun. 30 at 8:42 AM

$PALI

0 · Reply

Bull_Not_Bullish Jun. 30 at 8:38 AM

$PALI 3+ today

0 · Reply

SkywalkerAR Jun. 30 at 8:30 AM

0 · Reply

SadyK189 Jun. 30 at 1:56 AM

0 · Reply

Machiaveltrade Jun. 29 at 8:51 PM

$PALI and $ABVX my two precious….never sell 😁

0 · Reply

Machiaveltrade Jun. 29 at 8:26 PM

$PALI major position here and no sell …LT hold

0 · Reply

balzofsteel Jun. 29 at 6:19 PM

$PALI I’m balls deep in PALI. And I’m not ready to dump. More like I’m ready to hump . See y’all at $20

1 · Reply

StocktwitsNews Jun. 29 at 5:49 PM

PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? $PALI https://stocktwits.com/news/equity/markets/palisade-bio-pali-stock-rally-fda-ind-approval-ulcerative-colitis-drug/cZ190XcR7LW

0 · Reply

Muslimmah Jun. 29 at 5:25 PM

$PALI FDA approval.

0 · Reply

notreload_ai Jun. 29 at 4:49 PM

The FDA has cleared $PALI investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026. https://notreload.xyz/xy/palisade-bio-jumps-after-fda-clears-pali-2108-phase-2/

0 · Reply

ronburgandy75 Jun. 29 at 2:04 PM

$PALI i guessback to baseline $2.00

0 · Reply

ronburgandy75 Jun. 29 at 1:59 PM

$PALI should be above $3.X

0 · Reply

ronburgandy75 Jun. 29 at 1:58 PM

$PALI can this really climb on good news?

0 · Reply

Muslimmah Jun. 29 at 1:40 PM

$PALI let’s go, finally after a very very long wait.

0 · Reply

Stock_Catcher Jun. 29 at 12:31 PM

$PALI Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis

0 · Reply

Merlintrader Jun. 25 at 3:07 PM

$PALI Russell 2026 Biotech Watchlist: $CNTX $IMMX $CBIO and the Small-Cap Health Care Additions to Watch https://www.merlintrader.com/russell-2026-biotech-watchlist/

0 · Reply

Stormy02 Jun. 23 at 4:46 PM

$MWYN $OCGN $PALI Thanks

0 · Reply

Unicorno Jun. 19 at 1:04 PM

$PALI come on let s start this study management!!! i want 2.7$ at the news!!!

0 · Reply

focafoca99 Jun. 11 at 9:53 PM

$PALI just got a board addition, a bigger share count, and shareholder approval for equity plans after its annual meeting.

0 · Reply

Market Cap	364.52M
Revenue (ttm)	0.00
Net Income (ttm)	-16.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,352,600
Avg Vol	3,725,086
Day's Range	N/A - N/A
Shares Out	173.58M
Stochastic %K	63%
Beta	1.50
Analysts	Strong Sell
Price Target	$10.67